ANDA 205080, held by Amneal Pharmaceuticals. Itraconazole.
As of Nov 21, 2026, ANDA 205080 (Itraconazole), held by Amneal Pharmaceuticals, was first approved by FDA on Sep 26, 2016, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 26, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Itraconazole100MG · capsule;oral | Itraconazole | Rx |
| Sep 14, 2026 | Supplement 20Labeling · Standard review | Approved | None posted |
| Mar 10, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Mar 10, 2025 | Supplement 18Labeling · Standard review | Approved | None posted |
| Jul 10, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 6, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 11, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 26, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters